vs
FIRSTSUN CAPITAL BANCORP（FSUN）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
VERACYTE, INC.的季度营收约是FIRSTSUN CAPITAL BANCORP的1.3倍（$139.1M vs $110.0M），VERACYTE, INC.净利率更高（20.6% vs 19.6%，领先1.0%），过去两年VERACYTE, INC.的营收复合增速更高（10.2% vs 6.9%）
FirstSun Capital Bancorp是一家总部位于美国的金融控股公司，提供商业及个人贷款、存款产品、财富管理、财资解决方案等全面的银行金融服务，主要面向美国区域市场的个人消费者、中小企业及企业客户。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
FSUN vs VCYT — 直观对比
营收规模更大
VCYT
是对方的1.3倍
$110.0M
净利率更高
VCYT
高出1.0%
19.6%
两年增速更快
VCYT
近两年复合增速
6.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $110.0M | $139.1M |
| 净利润 | $21.6M | $28.7M |
| 毛利率 | — | 72.7% |
| 营业利润率 | — | 16.3% |
| 净利率 | 19.6% | 20.6% |
| 营收同比 | — | 21.5% |
| 净利润同比 | -8.4% | — |
| 每股收益（稀释后） | $0.76 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSUNVCYT
| Q1 26 | $110.0M | $139.1M | ||
| Q4 25 | $110.2M | $140.6M | ||
| Q3 25 | $107.3M | $131.9M | ||
| Q2 25 | $105.6M | $130.2M | ||
| Q1 25 | $96.2M | $114.5M | ||
| Q4 24 | $98.7M | $118.6M | ||
| Q3 24 | $98.2M | $115.9M | ||
| Q2 24 | $96.2M | $114.4M |
净利润FSUNVCYT
| Q1 26 | $21.6M | $28.7M | ||
| Q4 25 | $24.8M | $41.1M | ||
| Q3 25 | $23.2M | $19.1M | ||
| Q2 25 | $26.4M | $-980.0K | ||
| Q1 25 | $23.6M | $7.0M | ||
| Q4 24 | $16.4M | $5.1M | ||
| Q3 24 | $22.4M | $15.2M | ||
| Q2 24 | $24.6M | $5.7M |
毛利率FSUNVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | — | 69.2% | ||
| Q2 25 | — | 69.0% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | — | 66.4% | ||
| Q3 24 | — | 68.2% | ||
| Q2 24 | — | 68.1% |
营业利润率FSUNVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | 29.0% | 26.4% | ||
| Q3 25 | 26.4% | 17.4% | ||
| Q2 25 | 31.2% | -4.0% | ||
| Q1 25 | 30.9% | 2.5% | ||
| Q4 24 | 20.4% | 3.5% | ||
| Q3 24 | 29.1% | 10.4% | ||
| Q2 24 | 32.3% | 4.0% |
净利率FSUNVCYT
| Q1 26 | 19.6% | 20.6% | ||
| Q4 25 | 22.5% | 29.3% | ||
| Q3 25 | 21.6% | 14.5% | ||
| Q2 25 | 25.0% | -0.8% | ||
| Q1 25 | 24.5% | 6.2% | ||
| Q4 24 | 16.6% | 4.3% | ||
| Q3 24 | 22.8% | 13.1% | ||
| Q2 24 | 25.5% | 5.0% |
每股收益（稀释后）FSUNVCYT
| Q1 26 | $0.76 | $0.35 | ||
| Q4 25 | $0.89 | $0.50 | ||
| Q3 25 | $0.82 | $0.24 | ||
| Q2 25 | $0.93 | $-0.01 | ||
| Q1 25 | $0.83 | $0.09 | ||
| Q4 24 | $0.57 | $0.07 | ||
| Q3 24 | $0.79 | $0.19 | ||
| Q2 24 | $0.88 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $413.7M | $439.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $1.3B |
| 总资产 | $8.6B | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FSUNVCYT
| Q1 26 | $413.7M | $439.1M | ||
| Q4 25 | $652.6M | $362.6M | ||
| Q3 25 | $659.9M | $315.6M | ||
| Q2 25 | $785.1M | $219.5M | ||
| Q1 25 | $621.4M | $186.1M | ||
| Q4 24 | $615.9M | $239.1M | ||
| Q3 24 | $573.7M | $274.1M | ||
| Q2 24 | $535.8M | $235.9M |
股东权益FSUNVCYT
| Q1 26 | $1.2B | $1.3B | ||
| Q4 25 | $1.2B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $996.6M | $1.1B |
总资产FSUNVCYT
| Q1 26 | $8.6B | $1.4B | ||
| Q4 25 | $8.5B | $1.4B | ||
| Q3 25 | $8.5B | $1.4B | ||
| Q2 25 | $8.4B | $1.3B | ||
| Q1 25 | $8.2B | $1.3B | ||
| Q4 24 | $8.1B | $1.3B | ||
| Q3 24 | $8.1B | $1.3B | ||
| Q2 24 | $8.0B | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $35.2M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.23× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流FSUNVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $111.5M | $52.6M | ||
| Q3 25 | $49.4M | $44.8M | ||
| Q2 25 | $15.0M | $33.6M | ||
| Q1 25 | $26.4M | $5.4M | ||
| Q4 24 | $101.1M | $24.5M | ||
| Q3 24 | $48.1M | $30.0M | ||
| Q2 24 | $20.9M | $29.6M |
自由现金流FSUNVCYT
| Q1 26 | — | — | ||
| Q4 25 | $104.0M | $48.8M | ||
| Q3 25 | $47.6M | $42.0M | ||
| Q2 25 | $13.0M | $32.3M | ||
| Q1 25 | $24.3M | $3.5M | ||
| Q4 24 | $95.7M | $20.4M | ||
| Q3 24 | $47.1M | $27.7M | ||
| Q2 24 | $19.9M | $26.8M |
自由现金流率FSUNVCYT
| Q1 26 | — | — | ||
| Q4 25 | 94.3% | 34.7% | ||
| Q3 25 | 44.4% | 31.8% | ||
| Q2 25 | 12.3% | 24.8% | ||
| Q1 25 | 25.3% | 3.1% | ||
| Q4 24 | 97.0% | 17.2% | ||
| Q3 24 | 47.9% | 23.9% | ||
| Q2 24 | 20.6% | 23.4% |
资本支出强度FSUNVCYT
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 2.7% | ||
| Q3 25 | 1.6% | 2.1% | ||
| Q2 25 | 1.9% | 1.0% | ||
| Q1 25 | 2.1% | 1.6% | ||
| Q4 24 | 5.5% | 3.5% | ||
| Q3 24 | 1.1% | 1.9% | ||
| Q2 24 | 1.1% | 2.4% |
现金转化率FSUNVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | 4.49× | 1.28× | ||
| Q3 25 | 2.13× | 2.34× | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | 1.12× | 0.76× | ||
| Q4 24 | 6.18× | 4.80× | ||
| Q3 24 | 2.15× | 1.98× | ||
| Q2 24 | 0.85× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSUN
| Net Interest Income | $82.8M | 75% |
| Noninterest Income | $27.2M | 25% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
